Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 1:13:4373-4381.
doi: 10.2147/CMAR.S304980. eCollection 2021.

Survival of Patients with Lung Cancer in the Setting of Liver Cirrhosis: A Multicenter Propensity Score Matching Study

Ming-Shian Lu  1 , Hung-I Lu  2 , Tzu-Ping Chen  3 , Che-Chia Chang  1 , Tsung-Ming Yang  4 , Miao-Fen Chen  5   6
Affiliations

Survival of Patients with Lung Cancer in the Setting of Liver Cirrhosis: A Multicenter Propensity Score Matching Study

Ming-Shian Lu et al. Cancer Manag Res. .

Abstract

Purpose: The survival outcome of lung cancer patients with coexisting liver cirrhosis has thus far received limited attention in the literature. In this study, we evaluated whether liver cirrhosis is an independent risk factor for the survival of patients with lung cancer.

Materials and methods: We conducted a retrospective, multicenter, propensity-matched study of lung cancer patients with and without liver cirrhosis. To determine differences in survival, we sought to identify risk factors associated with poor outcomes using Kaplan-Meier survival analysis and Cox proportional hazards regression.

Results: There were no statistically significant differences in the baseline clinical characteristics of patients between the cirrhosis and non-cirrhosis groups. The median overall survival of patients with and without cirrhosis was 13.07 months (95% confidence interval [CI]: 10.56-16.84) and 13.67 months (95% CI: 10.42-16.91), respectively (p=0.76). Cox proportional hazards regression analysis revealed that liver cirrhosis was not an independent risk factor for poor outcome (hazard ratio [HR]: 1.057, 95% CI: 0.805-1.388, p=0.690). In patients with cirrhosis, lower serum albumin levels, higher Charlson Comorbidity Index score, advanced-stage lung cancer, and treatment modality were factors associated with poor outcome. Increase in serum albumin by 1 g was associated with a 30% reduction in the risk of mortality (HR: 0.700, 95% CI: 0.494-0.993, p=0.045). While every point increase in the Charlson Comorbidity Index score by 1 point was linked to a 9% higher risk of mortality (HR: 1.090, 95% CI: 1.023-1.161, p=0.007).

Conclusion: The survival rates of lung cancer patients with and without cirrhosis did not differ significantly. Higher serum albumin levels and lower Charlson Comorbidity Index scores were associated with improved survival.

Keywords: liver cirrhosis; lung neoplasm; outcome; survival.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to report in this work.

Figures

Figure 1
Figure 1
Patient selection and matching process.
Figure 2
Figure 2
Survival curve for lung cancer patients with and without cirrhosis. There was no statistically significant difference in survival for WITH-Cirrhosis and WITHOUT-Cirrhosis lung cancer patients. The median overall survival for patients WITH-Cirrhosis was 13.07 months (95% CI 10.56–16.84) compared to 13.67 months (95% CI 10.42–16.91) for patients WITHOUT-Cirrhosis, p=0.76.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590 - DOI - PubMed
    1. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2017. Bethesda, MD: National Cancer Institute. Based on November 2019 SEER data submission, posted to the SEER web site; April, 2020. Available from: https://seer.cancer.gov/csr/1975_2017/. Accessed May19, 2021.
    1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736–1788. - PMC - PubMed
    1. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history, and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–231. doi:10.1016/j.jhep.2005.10.013 - DOI - PubMed
    1. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383(9930):1749–1761. doi:10.1016/S0140-6736(14)60121-5 - DOI - PubMed